Evofem Biosciences, Inc. (EVFM) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to EvoFem's Biosciences second quarter 2021 results call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1 on your telephone. Please be advised that today's conference is being recorded. I would now like to turn the call over to EvoFem's Vice President of Investor Relations, Amy Raskoff. Thank you, and good afternoon, everyone. If you haven't done so already, I encourage you to access the second quarter of 2021 presentation and the press release we issued earlier today, both of which are at evofem.com under the Investors tab. Before we begin, I would like to remind you that remarks on this call will contain forward-looking statements, which are made only as of today, August 11, 2021. For a more detailed description of important risk factors that could cause our actual results to differ materially, please refer to our annual report on Form 10-K and our most recent file, 10-Q. With that, I'll turn the call over to Sandra Pelletier, EvoFem's CEO. Thank you, Amy, and thanks, everyone, for joining us today. FFM delivered strong and sustainable growth in the second quarter of 2021. This includes 47% growth in Phexie prescriptions and 65% growth in units dispensed. And it also includes a 52% increase in the number of healthcare providers prescribing Phexie. We achieved this despite an ongoing and ever-changing pandemic and a time when many companies bemoaned the impact of COVID on their results, we are delivering and we are growing. The measure of a company's choices in people, strategy, and ability to execute is often best seen in times of crisis. It's much easier to perform when doctors' office...